



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/777,518	02/12/2004	Edward Roydon Jost-Price	50164/033002	6397
21559	7590	01/29/2008	EXAMINER	
CLARK & ELBING LLP			KIM, JENNIFER M	
101 FEDERAL STREET			ART UNIT	
BOSTON, MA 02110			PAPER NUMBER	
			1617	
			NOTIFICATION DATE	
			DELIVERY MODE	
			01/29/2008	
			ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com

Office Action Summary

Application No.

10/777,518

Applicant(s)

JOST-PRICE ET AL.

Examiner

Jennifer Kim

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 November 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-61 is/are pending in the application.
- 4a) Of the above claim(s) 4, 5, 8-14, 16-21, 23-27, 30-56 and 61 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3, 6, 7, 15, 22, 28, 29 and 57-60 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>1/26/07; 8/4/06</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicants' election without traverse of Group I drawn to a composition and a kit comprising a non-steroidal immunophilin-dependent immunosuppressant (NSIDI) and an NsIDI enhancer (NsIDIE) in amount that together are sufficient in vivo to decrease proinflammatory cytokine secretion or production or to treat an immunoinflammatory disorder with **cyclosporin A** as a species of NsIDI, **sertraline** as a species of NsIDI enhancer, and **epinephrine** as a species of the third agent is acknowledged.

Accordingly, claims 4, 5, 8-14, 16-21, 23-27, 30-56 and 61 are withdrawn from consideration since they are non-elected invention. Claims 1-3, 6, 7, 15, 22, 28, 29 and 57-60 have been examined only to the extent of applicants' election.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-3, 6, 7, 15, 22, 28, 29 and 57-60 are rejected under 35 U.S.C. 102(a) as being anticipated by Manivasakam et al. (WO 2004/030518 A2) of record.

Manivasakam et al. teach compositions and kits comprising SSRI (e.g. sertraline) and a non-steroidal immunophilin-dependent immunosuppressant (NslDI) (e.g. cyclosporine), optionally with other agent (epinephrine). (page 38, lines 18-23, page 25, page 39). Manivasakam et al. also teach a pharmaceutical composition and a kit with instructions comprising an SSRI and a second compound such as beta receptor agonist (epinephrine) and non-steroidal calcineurin inhibitor (cyclosporin). (claims 58, 65, 66, 75 and 76 on page 100-102). Manivasakam et al. teach that for the treatment of inflammatory bowel disease, non-steroidal calcineurin inhibitors such as cyclosporine can be employed with SSRI. (page 37, lines 1-15). Manivasakam et al. teach that the composition can be formulated for topical administration or systemic administration. (page 2, lines 10-11).

Accordingly, the reference relied on meets all of the elements of the claimed invention, thus, the instant claims are properly rejected under 35 U.S.C. 102(a).

None of the claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 6:30 am to 3 pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax

Application/Control Number:
10/777,518
Art Unit: 1617

Page 4

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Jennifer Kim
Primary Examiner
Art Unit 1617

Jmk
January 21, 2008